Chimeric antigen receptor T cell (CART) products have demonstrated promise as a treatment for relapsed or refractory pediatric acute lymphocytic leukemia (ALL) and adult relapsed or refractory diffuse large B cell lymphoma (DLBCL). Logistical complexities, requisite release testing, and other considerations currently favor a centralized manufacturing approach where the apheresis product is shipped fresh or frozen to a centralized manufacturing site and the final product is manufactured and cryopreserved, shipped frozen to the infusing center, and then infused.
No takes yet. Share an insight, caveat, or question.
Patrick J. Hanley (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: